Investing.com - Regeneron Pharma (NASDAQ: REGN) reported third quarter EPS of $11.59, $0.84 better than the analyst estimate of $10.75. Revenue for the quarter came in at $3.36B versus the consensus estimate of $3.23B.
Regeneron Pharma's stock price closed at $791.27. It is up 3.24% in the last 3 months and up 11.65% in the last 12 months.
Regeneron Pharma saw 11 positive EPS revisions and 9 negative EPS revisions in the last 90 days. See Regeneron Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Regeneron Pharma's Financial Health score is "great performance".
Check out Regeneron Pharma's recent earnings performance, and Regeneron Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar